<DOC>
	<DOCNO>NCT00360737</DOCNO>
	<brief_summary>The primary purpose study evaluate safety 7 Botulinum Antitoxin Serotypes derive horse use various laboratory measurement , clinical examination adverse event . In addition , follow intravenous ( injected vein ) administration assess much 7 Botulinum Antitoxin remain body .</brief_summary>
	<brief_title>Safety Study 7 Botulinum Antitoxin Serotypes Derived From Horses</brief_title>
	<detailed_description>Clostridial toxin amongst toxic substance know science ( Middlebrook , 1995 ) . In United States country , human exposure Clostridium botulinum toxin usually occur food poisoning , wind botulism colonize infection neonate . Recent event heighten concern possibility botulinum toxin use bioterrorist attack . In order prepared biological attack well usual human exposure , numerous therapeutic product currently undergo development treat prevent botulism , include use human equine derive antibody post-exposure prophylaxis botulinum toxin exposure ( Gelzleichter et al , 1999 ; Hibbs et al , 1996 ; Metzger Lewis , 1979 Keller Stiehm , 2000 ) . Botulinum antitoxins use treat adult exposure botulinum toxin least 40 year ( Cupo et al , 2001 ) . The use botulinum antitoxins treat individual expose botulinum toxin similar use passive immune therapy immune globulin collect immunized convalesce human donor treat wide range bacterial viral infectious disease ( Chippaux et al , 1998 ) . NP-018 ( heptavalent equine-derived botulinum antitoxin ) prepare plasma obtain horse immunize specific subtype botulinum toxoid toxin . Each individual horse immunize single botulinum toxin subtype . Plasma pool horse immunize botulinum toxin subtype . For antitoxin serotype ( A-G ) , despeciated product produce pepsin digestion IgG monomer equine plasma , yield predominantly F ( abÂ¢ ) 2 fragment . Following formulation , seven antitoxin serotypes blend heptavalent product fill single-use vial . The present clinical study intend assess pharmacokinetics safety NP 018 follow intravenous administration . The pharmacokinetics NP 018 comparable equine derive antitoxin product . NP 018 safe administer normal healthy volunteer .</detailed_description>
	<mesh_term>Antitoxins</mesh_term>
	<mesh_term>Botulinum Antitoxin</mesh_term>
	<criteria>Bodymass index 20 30 minimum body weight 111 lb ( 50 kg ) . For female subject surgically sterilize , willingness use effective method contraception throughout trial include : Using hormonal contraception ( oral injectable implant ) continuously 3 month prior start trial willing continue use hormonal contraception throughout entire trial . IUD insert least 2 month prior dose . For female subject postmenopausal less 2 year FSH &gt; = 40 mIU/mL must obtain . IF FSH &lt; 40 mIU/mL subject must agree use acceptable form contraception ( see acceptable form contraception . Normal healthy determine medical history , physical examination , ECG , vital sign test liver , kidney hematological function . Written Informed Consent Any know documented allergy horse ( e.g . rash , wheezing , rhinitis etc . exposure horse ) Any know documented allergy horse serum ( observation adverse event treatment kind product contain horse serum ) Any severe food allergy , seasonal allergy hay fever require therapy treatment immunosuppressive drug Known acute chronic asthma require treatment immunosuppressive drug History hypersensitivity blood product derive human equine source Heavy smoker ( &gt; 10 cigarette day ) Use nicotine containing product Use investigational product within past 30 day Pregnancy lactation Positive serological test HIV , HBV , HCV History , suspect substance abuse problem ( include alcohol ) failure alcohol drug screen screen baseline Individuals history allergy latex rubber Hemoglobin level &lt; 12 g/dL . Significant blood loss blood donation within 56 day prior dose . Any plasma donation within 7 day prior dose . Demonstrated potential allergic reaction NP018 base positive horse dander ( E3 ) IgE test positive NP018 skin sensitivity test prior dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Clinical Trials</keyword>
	<keyword>Investigational Drug</keyword>
	<keyword>Healthy Volunteers</keyword>
	<keyword>Botulinum Antitoxin</keyword>
	<keyword>Phoenix , Arizona</keyword>
</DOC>